Estimation of Fibrinogen Level among Sudanese Patients with Myocardial Infraction

  • Mohammed AL Mustafa Ahmed Edres Darfur University College, Sudan
  • Nihad Elsadig Babiker Faculty of Medical Laboratory Sciences, National University, Sudan

Abstract

Myocardial infraction (AMI) is an irreversible myocardial injury and necrosis caused by serious and long-term ischemia. It is generally seen in middle aged men with high risk factors for coronary artery disease. Only 4% of patients with AMI are under 40 years of age. This was a cross sectional study conducted at AL SHAB hospital, Khartoum, Sudan, aimed to estimate the fibrinogen level among Sudanese patients with myocardial infraction. 50 patients attending Alshab Hospital and diagnosed with MI used as a case group and 50 apparently healthy individuals with no history of MI were selected as control group. 1.8 ml of blood samples has been collected in sodium citrate anticoagulant container for measurement of fibrinogen level by clauss method in coagulometer device. It is clearly significant increase in fibrinogen level in myocardial infraction patient (p.value 0.000). In addition, the prothrombin time and gender were insignificantly differences in (AMI) patients. In the other hand, age and smoking significantly increased as risk factor in myocardial infraction. This study concluded that fibrinogen level was significantly increased in Sudanese patients with  myocardial infraction.


Keywords: Myochardial Infraction, Fibrinogen, Prothrombin Time, Coagulometer

Downloads

Download data is not yet available.

References

1. Lamm G. The epidemiology of acute myocardial infarction inyoung age groups. In: Roskamm H ed. Myocardial infarction at young age. Springer-Verlag, Berlin 1981: 5-7.
2. Wilhelmsen L, Svärsudd K, Korsan-Bengtsen K, Larsson B, Welin L,Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984; 311:501–505.
3. Ernst E, Koenig W, Lowe GDO, Meade TW, eds. Fibrinogen: A “New” Cardiovascular Risk Factor. Vienna, Austria: Blackwell-MZW; 1992.
4. Gabay C, Kushner I. Acute-phase proteins and other systemic responsesto inflammation. N Engl J Med. 1999; 340:448–454.
5. Lowe GDO. Blood rheology, haemostasis and vascular disease. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haemostasis and Thrombosis. 3rd ed. Edinburgh, UK: Churchill Livingstone; 1994: 1169–1188.
6. Ernst E, Resch K. L. Fibrinogen as a cardiovascular risk factor: Ameta-analysis and review of the literature. Ann Intern Med. 1993;118: 956–963.
7. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336:973–979.
8. Trell E. Community-based preventive medical department for individualrisk factor assessment and intervention in an urban population Prev Med. 1983; 2:397–402.
9. Ersan Tatli, Fatih Ozcelik, Meryem Aktoz . plasma fibrinogen level may predict critical coronary artery stenosis in young adults with myocardial infarction. Cardiology journal 2009; 318.
10. Lamm G. The epidemiology of acute myocardial infarction inyoung age groups. In: Roskamm H ed. Myocardial infarction at young age. Springer-Verlag, Berlin 1981: 5–7.
11. Elif Elmas, Thorstenkaelsch, Christianwolpert. Markers of thrombin formation are transiently increased in patients with VF during the acute phase of MI. Clin. Cardiol 2006; (29): 165–169.
12. Mohammad Shojaie,Morteza Pourahmad ,Ahad eshraghian ,Hamid Reza izadi ,Farzan naghshvar. Fibrinogen as a risk factor for premature myocardial infarction in iranian patients. Vascular Health and Risk Management 2009; 5:674.
13. Ersan Tatli, Fatih Ozcelik, Meryem Aktoz . Plasma fibrinogen level may predict critical coronary artery stenosis in young adults with myocardial infarction. Cardiology journal 2009; 318
14. Wayne D. Rosamond, Thomas H. Mosley. Twenty-Two Year Trends in Incidence of Myocardial Infarction, CHD Mortality, and Case-Fatality in Four US Communities, 1987 to 2008. PMC 2013, (17):10.
15. Hamer M, Stamatakis E. Metabolically healthy obesity and risk of allcause and cardiovascular disease mortality. J Clin Endocrinol Metab 2012; 97:2482–8.
16. Ali NMA, Gameel, FEMH, Elsayid M, Babker AM. Alterations in D-Dimer, Prothrombin Time and Activated Partial Thromboplastin Time as Thrombogenesis Activity Markers in Patients with Acute Myocardial Infarction. Open Journal of Blood Diseases 2016; 6: 1-5.
17. Haseeb A, Khan, Abdullah S, Alhomida, Tamader Y, Al Rammah, Samia H, Sobki, Mohammad S, Ola, Adnan A Khan. PT and aPTT are significantly increased in AMI patients on anticoagulation. therapy.Epub 2013;297.
18. Ersan Tatli, Fatih Ozcelik, Meryem Aktoz . plasma fibrinogen level may predict critical coronary artery stenosis in young adults with myocardial infarction. Cardiology journal 2009; 319-320
19. Thomas AE, Green FR, Kelleher CH, Wilkes HC, Brennan PJ, MeadeTW, Humphries SE. Variation in the promoter region of the b fibrinogen gene is associated with plasma fibrinogen levels in smokers and in non-smokers. Thromb Haemost. 1991; 65:487–490.
20. ECAT Angina Pectoris Study Group. Baseline association of haemostatic factors with the extent of coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14: 8–17.
21. Engstrom G, Stavenow L, Hedblad B. Inflammation-sensitiveplasma proteins, stroke. diabetes, and mortality and incidence of myocardial infarction and A population-based study. Diabetes 2003; 52: 442–447.
22. Jun Zhu, Xiaohua Su, Gang Li, Jingsong Chen, Bing Tang, Yongjian Yang. Weight and weight change and risk of acute myocardial infarction and heart failure – the HUNT Study. Arch Med Sci 2014; 10 (5): 855–862.
23. Schargrodsky H, Rozlosnik J, Ciruzzi M, et al. Body weight and nonfatal myocardial infarction in a case-control study from Argentina. Soz Praventivmed 1994; 39: 126-33.
Statistics
39 Views | 58 Downloads
How to Cite
Edres, M. A. M. A., & Babiker, N. (2019). Estimation of Fibrinogen Level among Sudanese Patients with Myocardial Infraction. Journal of Drug Delivery and Therapeutics, 9(6-s), 21-27. https://doi.org/10.22270/jddt.v9i6-s.3737